US equities offer Australian investors access to some of the most innovative and fastest-growing companies in the world. The sheer depth of the American market means there are opportunities across sectors that simply do not exist on the ASX, from cutting-edge biotech platforms to global streaming businesses with hundreds of millions of subscribers. For investors looking to diversify beyond the financials and resources heavy ASX, a carefully selected allocation to US stocks can meaningfully improve portfolio quality and long-term return potential.
Investing in US equities also provides natural currency diversification. With the Australian dollar historically correlated to commodity cycles, holding US dollar denominated assets can reduce overall portfolio volatility and provide exposure to structural growth themes in technology, healthcare, and industrials that are underrepresented on the local exchange.
We apply the same institutional-grade research process to our US coverage as we do to ASX stocks. Each name on this list has been through a full assessment covering competitive positioning, earnings drivers, valuation, and management quality. We are looking for businesses with clear catalysts, defensible market positions, and a risk-reward profile that justifies the position at current prices. The five stocks below represent our highest conviction US ideas right now.
Last updated 15 April 2026.
| Stock | Rating | Price Target | Upside | Thesis |
| Broadcom (AVGO) | Buy | US$480.00 | 26.1% | Three hyperscaler partnerships lock in custom silicon and AI networking growth through 2031 |
| Netflix (NFLX) | Buy (upgraded from Neutral) | US$120.00 | 21.6% | Advertising revenue scaling, margin expansion, 18% pullback creating attractive entry |
| Waters Corporation (WAT) | Buy | US$375.00 | 25.9% | BD acquisition selloff overdone, pricing power transformation, PE declining to 16.3x by FY28E |
| ITT Inc (ITT) | Buy | US$270.00 | 49.1% | Industrial compounder with mid-teens EPS CAGR, SPX Flow deal accelerating 2030 earnings target |
| Amgen (AMGN) | Buy | US$415.00 | 19.1% | MariTide obesity catalyst, diversified pipeline acceleration, 15x forward PE with 3% yield |
Our Top 5 US Stocks To Buy Right Now
Broadcom Inc (AVGO)
Buy, 12-month price target US$480.00 (26.1% upside). Price target and upside based on prices at time of publication.
Broadcom is a global technology company with a market capitalisation of approximately US$1 trillion, operating across semiconductor solutions and infrastructure software. The company designs custom AI accelerators, networking chips, and broadband and storage semiconductors, and its infrastructure software segment was transformed by the 2023 acquisition of VMware. Broadcom’s customers include the world’s largest cloud and hyperscale data centre operators.
In the space of a single week, Broadcom has locked in multi-year partnerships with all three of the largest US hyperscalers. On April 6, the company announced a Long Term Agreement with Google to develop and supply future TPU generations through 2031, alongside an expanded collaboration with Anthropic for at least 3.5 GW of TPU-based AI compute capacity from 2027. Then on April 14, Broadcom announced a multi-year partnership with Meta for custom MTIA compute chips, with supply commitments extending to 2029 and an initial commitment exceeding 1 GW. Google and Anthropic alone are expected to contribute approximately 70% of Broadcom’s total AI XPU revenues in FY27 and FY28.
The revenue visibility from these agreements is exceptional. Total revenue is forecast at US$180.7 billion for FY27 and US$224.0 billion for FY28, with EPS estimates roughly 14% above Street consensus. At 30 times normalised earnings with a US$480 price target, we think there is meaningful upside from current levels as the market catches up to the scale of these commitments. Read the full article on Broadcom here.
Netflix Inc (NFLX)
Buy (upgraded from Neutral), 12-month price target US$120.00 (21.6% upside). Price target and upside based on prices at time of publication.
Netflix is the world’s largest streaming entertainment service with over 430 million paid subscribers across more than 190 countries. We have upgraded the stock to Buy from Neutral on the back of three converging pillars that we think the market is not fully pricing in. Sustained double-digit revenue growth is being driven by subscriber additions in LATAM and APAC, rising average revenue per member, and an advertising business that we expect to scale from US$1.5bn to approximately US$9.5bn by 2030.
The stock has pulled back 18% over the past six months, which creates an entry point that looks compelling relative to the earnings trajectory. We expect approximately 250 basis points of annual operating margin expansion as the advertising business scales and content spending grows more slowly than revenue. Netflix has demonstrated that it can consistently raise prices without meaningful subscriber churn, and the ad-supported tier is opening up a revenue stream that barely existed two years ago. With 70-75% free cash flow conversion, we also see potential for 20-25% of market capitalisation to be returned to shareholders through buybacks over the next five years.
The combination of a global subscriber base approaching half a billion users, a maturing advertising platform, and increasing capital returns makes Netflix a fundamentally different business than it was during the pandemic subscriber boom. We think the current valuation underestimates the durability of these growth drivers. Read the full article on Netflix here.
Waters Corporation (WAT)
Buy, 12-month price target US$375.00 (25.9% upside). Price target and upside based on prices at time of publication.
Waters Corporation is a global leader in analytical instruments and software used across pharmaceutical, life science, and industrial end markets. The company’s liquid chromatography and mass spectrometry platforms are essential tools in drug development, quality control, and clinical research. This is a business with deep customer relationships and high switching costs, which gives it durable pricing power and recurring revenue characteristics that are unusual for a hardware-centric company.
The stock has sold off following the BD Biosciences acquisition, and we think that reaction has created an attractive entry point. Waters has been undergoing a pricing power transformation, moving from roughly 50 basis points of annual price increases to 200 basis points, which flows directly to the bottom line. The BD deal brings flow cytometry and microbiology capabilities with strong pricing power and stickiness in regulated clinical settings. Cross-selling opportunities are significant, and the PE multiple is declining from 26.6x to 16.3x by FY28E as earnings growth catches up.
We see the current share price as an opportunity to buy a high-quality life sciences franchise at a discount driven by short-term integration noise rather than any fundamental deterioration. The combination of pricing power improvement, acquisition cost savings, and a recovery in end-market spending should drive earnings acceleration through 2027 and beyond. Read the full article on Waters Corporation here.
ITT Inc (ITT)
Buy, 12-month price target US$270.00 (49.1% upside). Price target and upside based on prices at time of publication.
ITT Inc is a diversified industrial manufacturer operating across three segments covering motion technologies, flow technologies, and connect and control technologies. The investment thesis centres on ITT being positioned as the next great industrial compounder. The company has delivered a decade of outgrowth in key end markets with more than 500 basis points of margin expansion, and we think there is significantly more runway ahead.
The SPX Flow acquisition is the key catalyst. It transforms the business and positions ITT for mid-teens EPS compound annual growth over the next three years. Management’s 2030 target of US$12 or more in earnings per share is tracking ahead of schedule, and consensus estimates are not yet fully reflecting the margin expansion and revenue synergies flowing through from the deal. ITT has a strong M&A track record with rapid de-leveraging, which gives us confidence that the integration will be executed well.
We think the market is under-appreciating the compounding power of this business. ITT has the right mix of end-market exposure, acquisition discipline, and operational improvement to sustain above-market earnings growth for several years. At 49.1% upside to our price target, this is one of the more attractive risk-reward setups in US industrials. Read the full article on ITT Inc here.
Amgen Inc (AMGN)
Buy, 12-month price target US$415.00 (19.1% upside). Price target and upside based on prices at time of publication.
Amgen is one of the world’s largest biotechnology companies with a diversified portfolio spanning cardiovascular, obesity, autoimmune, respiratory, and oncology therapeutics. The growth profile today looks materially different from the mature biotech narrative the market has applied for years. Key growth drivers include MariTide in obesity currently in Phase 3, Repatha in cardiovascular prevention, Tezspire in asthma, Uplizna in autoimmune conditions, and a deep biosimilars franchise that has generated US$13bn in cumulative revenue to date.
Management is confident on commercial execution across all of these franchises, and we see revenue accelerating as multiple products scale simultaneously. The biosimilar pipeline provides a steady stream of high-margin revenue with relatively low development risk compared to novel therapeutics. Amgen knows how to manufacture and commercialise complex biologics at scale, and the third wave of biosimilar products in development adds further visibility to the earnings trajectory.
At 15x forward earnings with a 3% dividend yield, Amgen offers a combination of value and growth that is difficult to find elsewhere in large-cap biotech. The company’s disciplined capital allocation, proven commercial execution, and diversified growth drivers make it a core holding candidate for investors looking for US healthcare exposure with downside protection. Read the full article on Amgen here.
How We Pick US Stocks for This List
Our selection process applies institutional-grade research to identify US-listed companies with compelling risk-reward profiles for Australian investors. We assess competitive positioning, earnings trajectory, management quality, and valuation against both historical ranges and global peers. Every stock on this list carries a Buy rating with a defined price target and a clear investment thesis backed by detailed fundamental analysis.
We focus on businesses with identifiable catalysts, whether that is an acquisition integration, a product cycle inflection, a margin expansion opportunity, or a valuation re-rating driven by improving fundamentals. We are not chasing momentum or speculative themes. The companies featured here have established or rapidly maturing market positions and offer a risk-reward profile that we think makes sense for investors looking to build long-term wealth through US equity exposure. We refresh this list as new research is completed.
If you would like to discuss any of these names or how US equities might fit within your portfolio, request a callback or call us on 1300 889 603.
